[
    [
        {
            "time": "2020-04-24",
            "original_text": "Coronavirus Stock Market Rally Pauses As Crude Oil Prices Go Negative; Netflix, Snap, Intel, Domino's, Chipotle, Eli Lilly Report",
            "features": {
                "keywords": [
                    "Coronavirus",
                    "Stock",
                    "Market",
                    "Rally",
                    "Pauses",
                    "Crude",
                    "Oil",
                    "Prices",
                    "Negative",
                    "Netflix",
                    "Snap",
                    "Intel",
                    "Domino's",
                    "Chipotle",
                    "Eli",
                    "Lilly"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "energy",
                    "technology",
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Coronavirus Stock Market Rally Pauses As Crude Oil Prices Go Negative; Netflix, Snap, Intel, Domino's, Chipotle, Eli Lilly Report",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "IBD",
                    "Long-Term",
                    "Leaders",
                    "Portfolio"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Moody's",
                    "rates",
                    "A2",
                    "stable",
                    "outlook"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "Will Eli Lilly and Company Continue to Surge Higher?",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Continue",
                    "Surge",
                    "Higher"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Will Eli Lilly and Company Continue to Surge Higher?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "Company News for Apr 24, 2020",
            "features": {
                "keywords": [
                    "Company",
                    "News",
                    "Apr",
                    "24",
                    "2020"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Company News for Apr 24, 2020",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 3,
                "Source_Recency": 2
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN",
            "features": {
                "keywords": [
                    "Pharma",
                    "Stock",
                    "Roundup",
                    "Q1",
                    "Earnings",
                    "LLY",
                    "Coronavirus",
                    "Update",
                    "PFE",
                    "NVS",
                    "AZN"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",
            "features": {
                "keywords": [
                    "Daily",
                    "Biotech",
                    "Pulse",
                    "FDA",
                    "Approves",
                    "Sanofi",
                    "Meningococcal",
                    "Vaccine",
                    "Pluristem",
                    "Secures",
                    "$54M",
                    "Funding",
                    "COVID-19",
                    "Treatment",
                    "Oric",
                    "Pharma",
                    "Prices",
                    "IPO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-04-24",
            "original_text": "What Is Eli Lilly's (NYSE:LLY) P/E Ratio After Its Share Price Rocketed?",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "P/E",
                    "Ratio",
                    "Share",
                    "Price",
                    "Rocketed"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Is Eli Lilly's (NYSE:LLY) P/E Ratio After Its Share Price Rocketed?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]